Caribou intends to utilize this scFv in the development of its CB-011 programme, an allogeneic CAR-T therapy targeting BCMA-positive tumors including multiple myeloma.
Under the terms of the agreement, ProMab received an upfront payment and is eligible for royalties on net sales of licensed products containing the BCMA scFv.
Caribou is a company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. The company is developing an internal pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes.
Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology.
ProMab Biotechnologies focuses on developing and commercialising mouse, rabbit, and human monoclonal antibodies as well as chimeric antigen receptor-T Cell (CAR-T) products.
ProMab's CAR-T platform covers both hematological and solid cancers with intensive in vitro and in vivo pre-clinical validation designed for safer and better treatment.
As a CRO in the immunology field for 19 years, ProMab offers standard laboratory procedures and animal studies for antibody discovery through the integration of the newest techniques in antibody library construction, next generation sequencing, unique humanization modeling, high-throughput screening, and artificial intelligence analysis systems.
ProMab aims to out-license antibodies validated in CAR-T therapy in the preclinical stage or to bring CAR-T technologies to the early stage market of clinical study.
ProMab has partnered with top biotechnology startups, medical institutions, and pharmaceutical companies to advance the development of cell therapies as well as bispecific antibodies targeting multiple cancers.
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
GSK announces submission of RSV vaccine Arexvy for FDA review
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
IGI and AbbVie enter global licensing agreement for ISB 2001
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
GenScript Biotech awarded EcoVadis Silver Medal
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025